Hereditary hemorrhagic telangiectasia: An overview of diagnosis and management in the molecular era for clinicians

Genetics in Medicine

Volumn 6, Issue 4, 2004, Pages 175-191

  Bayrak Toydemir, Pinar ^a,b   Mao, Rong ^b   Lewin, Susan ^a   McDonald, Jamie ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

ALK1; ENG; Genetic counseling; Hereditary hemorrhagic telangiectasia; Molecular diagnosis

Indexed keywords

ARTERIOVENOUS MALFORMATION; DIAGNOSTIC PROCEDURE; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; PATHOGENESIS; RENDU OSLER WEBER DISEASE; REVIEW; TREATMENT INDICATION;

GENETIC COUNSELING; GENETIC SCREENING; HUMANS; MUTATION; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 3442883144     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000132689.25644.7C     Document Type: Review

References (123)

1. Westermann CJ, Rosina AF, De Vries V, de Coteau PA. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet 2003;116A: 324-328.
2. Kjeldsen A, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-base study of prevalence and mortality in Danish patients. J Int Med 1999;245:31-39.
3. Plauchu H, Bideau A. Epidemiologie et constitution d'un registre de population a propos d'une concentration geographique d'une maladie hereditaire rare. Population 1984;39:765-786.
4. Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe M et al. Genetics epidemiology of hereditary hemorrhagic telangiectasia in a local community in the Northern Part of Japan. Hum Mutat 2002;19:140-148.
5. Morgan T, McDonald J, Anderson C, Ismail M, Miller F, Mao R et al. Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia. Pediatrics 2002;109:1-7.
6. Roman G, Fisher M, Perl D, Poser C. Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber Disease): Report of 2 cases and review of the literature. Ann Neurol 1978;4:130-144.
7. Kondziolka D, Humphreys R, Hoffman H, Hendrick EB, Drake J. Arteriovenous malformations of the brain in children: a forty year experience. Can J Neurol Sci 1992;19:40-45.
8. Mitchell R, Austin E. Pulmonary arteriovenous malformation in the neonate. J Pediatr Surg 1993;28:1536-1538.
9. Reichman H, Sorensen B. Excision of spinal cord arteriovenous malformation. Rocky Mt Med J 1971;68:21-24.
10. Guttmacher A, Marchuk D, White R. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-924.
11. Wallace G, Shovlin C. A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlined to the known HHT genes, endoglin and ALK-1. Thorax 2000;55:685-690.
12. Shovlin C, Guttmacher A, Buscarini E, Faughnan M, Hyland R, Westermann C et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber Syndrome). Am J Med Genet 2000;91:66-67.
13. Assar A, Friedman C, White R. The natural history of epistaxis in hereditary hemorrhagic telangiectases. Laryngoscope 1991;101:977-980.
14. Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary haemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989;32:291-297.
15. Porteous M, Burn J, Proctor S. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet 1992;29:527-530.
16. Kjeldsen A, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000;95:415-418.
17. Vase P, Holm M, Arendrup H. Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand 1985;218:105-109.
18. Haitjema T, Disch F, Overtoom T, Westermann C, Lammers J. Screening family members of patients with hereditary hemorrhagic telangiectasia. Am J Med 1995;99:519-524.
19. Kjeldsen A, Oxhoj H, Andersen P, Green A, Vase P. Prevalence of pulmonary arteriovenous malformations (PAVMs) and occurrence of neurological symptoms in patients with hereditary haemorrhagic telangiectasia (HHT). J Int Med 2000;248:255-262.
20. Shovlin C, LeTarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999;54:714-729.
21. White R. Pulmonary arteriovenous malformations: how do we diagnoses them and why is it important to do so? Radiology 1992;182:633-635.
22. Ference B, Shannon T, White R, Zawin M, Burdge C. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994;106:1387-1390.
23. Moussouttas M, Fayad P, Rosenblatt M, Hashimoto M, Pollak J, Henderson K et al. Pulmonary arteriovenous malformations: cerebral ischemia and neurologic manifestations. Neurology 2000;55:959-964.
24. White R, Pollak J, Wirth J. Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. J Vasc Interv Radiol 1996;7:787-804.
25. Hewes R, Auster M, White R. Cerebral embolism: first manifestation of pulmonary arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Cardiovasc Inter Rad 1985;8:151-155.
26. Shovlin C, Winstock A, Peters A, Jackson J, Hughes J. Medical complications of pregnancy in hereditary hemorrhagic telangiectasia. Q J Med 1995;88:879-887.
27. Fulbright R, Chaloupka J, Putman C, Sze G, Merriam M, Lee G et al. MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neurol Radial 1998;19:477-484.
28. Matsubara S, Manzia J, ter Brugge K, Willinsky R, Montanera W, Faughnan M. Angiographic and clinical characteristics of patients with cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia. Am J Neuroradiology 2000;21:1016-1020.
29. Willemse R, Mager J, Westermann C, Overtoom T, Mauser H, Wolbers J. Bleeding risk of cerebrovascular malformation in hereditary hemorrhagic telangiectasia. J Neurosurg 2000;92:779-784.
30. Mont'Alverne F, Musacchio M, Tolentino V, Belzile F, Riquelme C, Tournade A. Giant spinal perimedullary fistula in hereditary haemorrhagic telangiectasia: diagnosis, endovascular treatment and review of the literature. Neuroradiology 2003;45:830-836.
31. Garcia-Tsao G, Korzenik J, Young L, Henderson K, Jain D, Byrd B et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000;343:931-936.
32. Memeo M, Stabile Ianora AA, Scardapane A Buonamico P, Sabba C, Angelelli G. Hepatic involvement in hereditary hemorrhagic telangiectasia: Abdom Imaging 2004. Epub ahead of print.
33. Ianora AA, Memeo M, Sabba C, Cirulli A, Rotondo A, Angelelli G. Hereditary hemorrhagic telangiectasia: multidetector row helical T assessment. Radiology 2004;230250-230259.
34. Saluja S, White RI. Hereditary hemorrhagic telangiectasia of the liver; Hyperperfusion with relative ischemia - poverty amidst plenty? Radiology 2004;230:25-27.
35. Buscarini E, Buscarini L, Danesino C, Pinatanida M, Civardi G, Quaretti P et al. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: Doppler sonographic screening in a large family. J Hepato 1997;26:111-118.
36. McDonald J, Miller F, Hallam S, Nelson L, Marchuk D, Ward K. Clinical manifestations in a large hereditary hemorrhagic telangiectasia type 2 kindred. Am J Med Genet 2000;93:320-327.
37. His DH, Ryan GF, Hellems SO, Cheeran DC, Sheils LA. Large aneurysms of the ascending aorta and major coronary arteries in a patient with hereditary hemorrhagic telangiectasia. Mayo Clin Proc 2003;78:774-776.
38. Tsuiki K, Tamada Y, Yasui S. Coronary artery aneurysm without stenosis in association with Osler-Weber-Rendu disease: A case report. Angiology 1991;42:55-58.
39. Brant A, Schachat A, White R. Ocular manifestations in hereditary hemorrhagic telangiectasia. Am J Ophthalmol 1989;107:642-646.
40. Vase I, Vase P. Ocular lesions in hereditary hemorrhagic telangiectasia. Acta Ophthalmol 1979;57:1084-1090.
41. Lande A, Bedford A, Schechter LS. The spectrum of arteriographic findings in Osler-Weber-Rendu disease. Angiology 1976;27:223-240.
42. Ziani M, Valignat C, Lopez J, Ruffion A, Plauchu H, Perrin P. Renal arteriovenous malformation requiring surgery in Rendu-Osler-Weber Disease. J Urololgy 2000;164:1292-1293.
43. Humphries JE, Frierson HF Jr, Underwood PB Jr. Vaginal telangiectasias: unusual presentation of the Osler-Weber-Rendu syndrome. Obstet Gynecol 1993;81:865-866.
44. Barzilai B, Waggoner A, Spessert C, Picus D, Goodenberger D. Two-dimensional contrast echocardiography in the detection and follow-up of congenital pulmonary arteriovenous malformations. Am J Cardiol 1991;68:1507-1510.
45. Kjeldsen A, Oxhoj H, Andersen P, Elle B, Jacobsen J, Vase P. Screening Procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia. CHEST 1999;116:432-439.
46. Nanthakumar K, Graham A, Robinson T, Grande P, Pugash R, Clarke J et al. Contrast echocardiography for detection of pulmonary arteriovenous malformations. Am Heart J 2001;141:243-246.
47. Remy J, Remy-Jardin M, Wattinne L, Deffontaines C. Pulmonary arteriovenous malformations: Evaluation with CT of the chest before and after treatment. Radiology 1992;182:809-816.
48. White R, Pollak J. Pulmonary arteriovenous malformations: diagnosis with three-dimensional helical CT: A breakthrough without contrast media. Radiology 1994;191:613-614.
49. Lee D, White R, Egglin T, Pollak J, Fayad P, Wirth J et al. Embolotherapy of large pulmonary arteriovenous malformations: long-term results. Ann Thorac Surg 1997;64:930-940.
50. Christenson G. Nosebleeds may mean something much more serious: an introduction to HHT. JADA 1998;129:635-637.
51. Parkin J, Dixon JA. Laser photocoagulation in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1981;89:204-208.
52. Shapshay S, Oliver P. Treatment of hereditary hemorrhagic telangiectasia by Nd-Yag laser photocoagulation. Laryngoscope 1984;94:1554-1556.
53. Saunders W. Septal dermoplasty for control of nosebleeds caused by hereditary hemorrhagic telangiectasia or septal perforations. Trans Am Acad Ophthalmol Otolaryngol 1960;64:500-506.
54. Longacre A, Gross C, Gallitelli M, Henderson K, White R, Proctor D. Diagnosis and management of gastrointestinal bleeding in patient with hereditary hemorrhagic telangiectasia. Am J Gastroenterology 2003 98:59-65.
55. Gershon A, Faughnan M, Chon K, Pugash R, Clark J, Bohan M et al. Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy. CHEST 2001;119:470-477.
56. Levy EI, Niranjan M, Thompson T, Scarrow A, Kondziolka D, Flickinger J et al. Radiosurgery for childhood intracranial arteriovenous malformations. Neurosurgery 2000;47:834-842.
57. Vinuela F, Dion J, Duckwiler G, Martin N, Lylyk P, Fox A et al. Combined endovascular embolization and surgery in the management of cerebral arteriovenous malformations: experience with 101 cases. J Neurosurg 1991;75:856-864.
58. Odorico J, Hakim M, Becker Y. Liver transplantation as definitive therapy for complication after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia. Liver Transpl Surg 1998;4:483-490.
59. Miller F, Whiting J, Korzenik J, White R. Caution with use of hepatic embolization in the treatment of hereditary hemorrhagic telangiectasia. Radiology 1999;213:928-930.
60. Boillot O, Bianco F. Viale J. Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement. Gastroenterology 1999;116:187-192.
61. Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M, Bernabeu C. Assignment of the human endoglin gene (END) to 9q34-qter. Cytogenet Cell Genet 1993;64:204-207.
62. McDonald MT, Papenberg KA, Ghosh S, Glatfelter AA, Biesecker BB, Helmbold EA et al. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat Genet 1994;6:197-204.
63. Shovlin CL, Hughes JM, Tuddenham EG, Temperley I, Perembelon YF, Scott J et al. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nat Genet 1994;6:205-209.
64. Vincent P, Plauchu H, Hazan J, Fauré S, Weissenbach J, Godet J. A third locus for hereditary haemorrhagic telangiectasia maps to chromosome 12q. Hum Mol Gen 1995;4:945-949.
65. Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995;5:21-28.
66. Roijer E, Miyazono K, Astrom AK, Geurts van Kessel A, ten Dijke P, Stenman G. Chromosomal localization of three human genes encoding members of the TGF-beta superfamily of type I serine/threonine kinase receptors. Mamm Genome 1998;9:266-268.
67. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-351.
68. Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE et al. The Activin receptor-like kinase 1 gene: Genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 1997;61:60-67.
69. Attisano L, Carcamo J, Venture F, Weis FM, Massagué J, Wrana JL. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993;5:671-680.
70. Cheifetz S, BellÓn T, Calés C, Vera S, Bernabeu C, Massagué J et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992;267:19027-19030.
71. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S et al. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993;23:2340-2345.
72. Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science 2002;296:646-1647.
73. ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H et al. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993;8:2879-2887.
74. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-195.
75. Gougos A, St Jacques S, Greaves A, O'Connell PJ, d'Apice AJ, Buhring HJ et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 1992;4:83-92.
76. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992;22:393-397.
77. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 1999;274:584-594.
78. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003-1014.
79. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341-347.
80. Wieser R, Wrana JL, Massagué J. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J 1995;14:2199-2208.
81. Massagué J. TGF-β signal transduction. Annu Rev Biochem 1998;67:753-791.
82. Derynck R, Zhang Y, Feng XH. Smads: Transcriptional activators of TGF-β responses. Cell 1998;95:737-740.
83. Gallione CJ, Repetto GM, Legius E, Rustig AK, Schelley SL, Tejpar S et al. A combined syndrome of juvenile polyposis with mutations in MADH4 (SMAD4). Lancet 2004;363:852-859.
84. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000;97:2626-2631.
85. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002;21:1743-1753.
86. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C et al. Activin receptor-like kinase (ALK) 1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003;12:817-828.
87. McAllister KA, Baldwin MA, Thukkani AK, Gallione CJ, Berg JN, Porteus AE et al. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum Mol Genet 1995;4:1983-1985.
88. Pece N, Vera S, Cymerman U, White R, Wrana J Jr, Letarte M. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J Clin Invest 1997;100:2568-2579.
89. Pece-barbara N, Cymerman U, Vera S, Marchuk D, Letarte M. Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 1999;8:2171-2181.
90. Paquet ME, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C et al. Analysis of several endoglin mutants reveals no endoglins mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 2001;10:1347-1357.
91. Lux A, Gallione CJ, Marchuk DA. Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms. Hum Mol Genet 2000;9:745-755.
92. Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE et al. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformation of patients with hereditary hemorrhagic telangiectasia type 1. Am J Path 2000;156:911-923.
93. Shovlin CL, Hughes JM, Scott J, Seidman CE, Seidman JG. Characterization of endoglin and dentification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 1997;61:68-79.
94. Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C et al. Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet 2000;9:1227-1237.
95. Klaus DJ, Gallione CJ, Anthony K, Yeh EY, Yu J, Lux A et al. Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Mutations in brief no. 164. Online. Hum Mutat 1998;12:137.
96. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003;40:865-871.
97. Abdalla SA, Cymerman U, Johnson RM, Deber CM, Letarte M. Disease-associated mutations in conserved residues of ALK-1 kinase domain. Eur J Hum Genet 2003;11:279-287.
98. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534-1537.
99. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E et al. Endoglin, an ancillary TGF beta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000;217:42-53.
100. Torsney E, Charlton R, Diamond AG, Burn J, Soames JV, Arthur HM. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 2003;107:1653-1657.
101. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000;26:328-331.
102. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003;12:473-482.
103. Seki T, Yun J, Oh P. Arterial endothelium-specific activin receptor-like kinasel expression suggests its role in arterialization and vascular remodeling. Circu Res 2003;3:1-9.
104. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999;104:1343-1351.
105. Roman BL, Pham VN, Lawson ND, Kulik M, Childs S, Lekven AC et al. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development 2002;129:3009-3019.
106. Gallione C, Scheessele EA, Reinhardt D, Duits AJ, Berg JN, Westermann CJ et al. Two common endoglin mutations in families with hereditary hemorrhagic telangiectasia in the Netherlands Antilles: evidence foe a founder effect. Hum Genet 2000;107:40-44.
107. Lesca G, Plauchu H, Coulet F, Lefebvre S, Plessis G, Odent S et al. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat 2004;23:289-299.
108. Berg J, Guttmacher A, Marchuk D, Porteous M. Clinical heterogeneity in hereditary hemorrhagic telangiectasia: are pulmonary arteriovenous malformation more common in families linked to endoglin? J Med Genet 1996;33:256-257.
109. Heutink P, Haitjema T, Breedveld G, Janssen B, Sandkuijl L, Bontekoe C et al. Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J Med Genet 1994;31:933-936.
110. Olivieri C, Mira E, Delu G, Pagella F, Zambelli A, Malvezzi L et al. Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia. J Med Genet 2002;39:E39.
111. Abdalla S, Geisthoff U, Bonneau D, Plauchu H, McDonald J, Kennedy S et al. Visceral manifestations in hereditary haemorrhagic telangiectasia type 2. J Med Genet 2003;40:494-502.
112. Cymerman U, Vera S, Amna K, Abdalla S, Letarte M. Characterization of 17 novel endoglin mutations associated with hereditary hemorrhagic telangiectasia. Hum Mutat 2003;21:482-492.
113. Piantanida M, Buscarini E, Dellavecchia C, Minelli A, Rossi A, Buscarini L et al. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 1996;33:441-443.
114. American College of Medical Genetics recommendations for standards for interpretation of sequence variations. Genet Med 2000;2:302-303.
115. Menasha J, Schechter C, Willner J. Genetic testing: A physician's perspective. Mt Sinai J Med 2000;67:144-155.
116. Gallione C, Klaus DJ, Yeh EY, Stenzel TT, Xue Y, Anthony KB et al. Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles. Hum Mutat 1998;11:286-294.
117. Cymerman U, Vera S, Pece-Barbara N, Bourdeau A, White R, Dunn Jr J et al. Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protwin expression and mutation analysis of endoglin. Pediat Res 2000;47:24-35.
118. Lastella P, Sabba C, Lenato GM, Resta N, Lattanzi W, Gallitelli M et al. Endoglin gene mutations and polymorphisms in Italian patients with hereditary haemorrhagic telangiectasia. Clin Genet 2003;63:536-540.
119. Yamaguchi H, Azuma H, Shigekiyo T, Inoue H, Saito S. A novel missense mutation in the endoglin gene in hereditary hemorrhagic telangiectasia. Thromb Haemost 1997;77:243-247.
120. Hereditary Hemorrhagic telangiectasia mutation database, Edinburg, Molecular Genetics Service 2003 Available at: http://137.195.14.43/genisysDR/ NVC/198/Display/index.htm.
121. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-334.
122. Kjeldsen AD, Brusgaard K, Poulsen L, Kruse T, Rasmussen K, Green A et al. Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families. Am J Med Genet 2001;98:298-302.
123. D'Abronzo FH, Swearingen B, Klibanski A, Alexander JM. Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors. J Clin Endocrinol Metab 1999;84:1716-1721.